

World Journal of *Psychiatry*

World J Psychiatr 2021 August 19; 11(8): 403-506



THERAPEUTIC AND DIAGNOSTIC GUIDELINES

- 403 Ultra-brief crisis interpersonal psychotherapy based intervention for suicidal children and adolescents
Klomek AB, Catalan LH, Apter A

REVIEW

- 412 Menopause and cognitive impairment: A narrative review of current knowledge
Conde DM, Verdade RC, Valadares ALR, Mella LFB, Pedro AO, Costa-Paiva L
- 429 Clozapine resistant schizophrenia: Newer avenues of management
Chakrabarti S

ORIGINAL ARTICLE**Case Control Study**

- 449 Impact of spiritual care on the spiritual and mental health and quality of life of patients with advanced cancer
Sun XH, Liu X, Zhang B, Wang YM, Fan L

SYSTEMATIC REVIEWS

- 463 Therapeutic use of melatonin in schizophrenia: A systematic review
Duan C, Jenkins ZM, Castle D

META-ANALYSIS

- 477 Hypomanic/manic switch after transcranial magnetic stimulation in mood disorders: A systematic review and meta-analysis
Miuli A, Sepede G, Stigliano G, Mosca A, Di Carlo F, d'Andrea G, Lalli A, Spano MC, Pettorruso M, Martinotti G, Di Giannantonio M

SCIENTOMETRICS

- 491 Knowledge domain and emerging trends in visual hallucination research: A scientometric analysis
Zhong M, Wu Z, Jiang X, Shen B, Zhu J, Zhang L

ABOUT COVER

Peer Reviewer of *World Journal of Psychiatry*, Qing-Zhong Wang, PhD, Associate Professor, Institute of Chinese Materia Medica, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China. wangqingzhong3@gmail.com

AIMS AND SCOPE

The primary aim of *World Journal of Psychiatry (WJP, World J Psychiatr)* is to provide scholars and readers from various fields of psychiatry with a platform to publish high-quality basic and clinical research articles and communicate their research findings online.

WJP mainly publishes articles reporting research results and findings obtained in the field of psychiatry and covering a wide range of topics including adolescent psychiatry, biological psychiatry, child psychiatry, community psychiatry, ethnopsychology, psychoanalysis, psychosomatic medicine, etc.

INDEXING/ABSTRACTING

The *WJP* is now abstracted and indexed in Science Citation Index Expanded (SCIE, also known as SciSearch®), Current Contents/Clinical Medicine, Journal Citation Reports/Science Edition, PubMed, and PubMed Central. The 2021 edition of Journal Citation Reports® cites the 2020 impact factor (IF) for *WJP* as 4.571; IF without journal self cites: 4.429; 5-year IF: 7.697; Journal Citation Indicator: 0.73; Ranking: 46 among 156 journals in psychiatry; and Quartile category: Q2.

RESPONSIBLE EDITORS FOR THIS ISSUE

Production Editor: *Lin-YuTong Wang*; Production Department Director: *Yu-Jie Ma*; Editorial Office Director: *Jia-Ping Yan*.

NAME OF JOURNAL

World Journal of Psychiatry

ISSN

ISSN 2220-3206 (online)

LAUNCH DATE

December 31, 2011

FREQUENCY

Monthly

EDITORS-IN-CHIEF

Rajesh R Tampi

EDITORIAL BOARD MEMBERS

<https://www.wjgnet.com/2220-3206/editorialboard.htm>

PUBLICATION DATE

August 19, 2021

COPYRIGHT

© 2021 Baishideng Publishing Group Inc

INSTRUCTIONS TO AUTHORS

<https://www.wjgnet.com/bpg/gerinfo/204>

GUIDELINES FOR ETHICS DOCUMENTS

<https://www.wjgnet.com/bpg/GerInfo/287>

GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH

<https://www.wjgnet.com/bpg/gerinfo/240>

PUBLICATION ETHICS

<https://www.wjgnet.com/bpg/GerInfo/288>

PUBLICATION MISCONDUCT

<https://www.wjgnet.com/bpg/gerinfo/208>

ARTICLE PROCESSING CHARGE

<https://www.wjgnet.com/bpg/gerinfo/242>

STEPS FOR SUBMITTING MANUSCRIPTS

<https://www.wjgnet.com/bpg/GerInfo/239>

ONLINE SUBMISSION

<https://www.f6publishing.com>

Therapeutic use of melatonin in schizophrenia: A systematic review

Cathy Duan, Zoe M Jenkins, David Castle

ORCID number: Cathy Duan 0000-0001-5809-2436; Zoe M Jenkins 0000-0002-8551-0792; David Castle 0000-0002-3075-1580.

Author contributions: Duan C and Castle D designed the research; Duan C performed the search; Duan C and Jenkins ZM extracted the data and wrote the paper; Castle D supervised the paper; all authors read and approved the final manuscript.

Conflict-of-interest statement: The authors have no conflicts of interest to declare.

PRISMA 2009 Checklist statement: The authors have read the PRISMA 2009 Checklist, and the manuscript was prepared and revised according to the PRISMA 2009 Checklist.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

Cathy Duan, Zoe M Jenkins, David Castle, Department of Psychiatry, University of Melbourne, Parkville 3010, VIC, Australia

Zoe M Jenkins, David Castle, Mental Health Service, St. Vincent's Hospital, Melbourne 3065, VIC, Australia

David Castle, Centre for Complex Interventions, Centre for Addictions and Mental Health, Toronto ON M6J 1H4, Canada

David Castle, Department of Psychiatry, University of Toronto, Toronto ON M5S, Canada

Corresponding author: Zoe M Jenkins, BSc, Research Fellow, Mental Health Service, St. Vincent's Hospital, 46 Nicholson Street, Fitzroy, Melbourne 3065, VIC, Australia.
zoe.jenkins@svha.org.au

Abstract

BACKGROUND

Sleep dysfunction is a common problem in people with schizophrenia, and side effects of treatment often exacerbate metabolic and cardiovascular risk and may induce extrapyramidal side effects. Melatonin (N-acetyl-5-methoxytryptamine) is an endogenously produced hormone which has demonstrated direct and indirect antioxidant and neuroprotective effects. Previous studies have explored the use of exogenous melatonin in improving sleep outcomes in the general population, yet indications for use in schizophrenia are unclear.

AIM

To synthesize the evidence from clinical trials investigating prescribed melatonin as an adjunctive therapy in patients with schizophrenia.

METHODS

A systematic literature review of MEDLINE (Ovid), Embase, PsychINFO, and PubMed on the 27/08/20; and CINAHL and Cochrane Library databases, was conducted. Inclusion criteria were: a peer-reviewed clinical trial published in English; included a group of patients with schizophrenia; used melatonin as an adjunctive therapy; and reported any outcome of any duration. Exclusion criteria were: neurodegenerative diseases, primary sleep disorders, co-morbid substance use or animal studies.

RESULTS

Fifteen studies were included in the current review with the following primary outcomes: sleep ($n = 6$), metabolic profile ($n = 3$), tardive dyskinesia ($n = 3$), cognitive function ($n = 2$) and benzodiazepine discontinuation ($n = 1$).

Manuscript source: Invited manuscript

Specialty type: Psychiatry

Country/Territory of origin: Australia

Peer-review report's scientific quality classification

Grade A (Excellent): A
Grade B (Very good): 0
Grade C (Good): 0
Grade D (Fair): 0
Grade E (Poor): 0

Received: February 24, 2021

Peer-review started: February 24, 2021

First decision: July 4, 2021

Revised: July 12, 2021

Accepted: July 29, 2021

Article in press: July 29, 2021

Published online: August 19, 2021

P-Reviewer: Hosak L

S-Editor: Gao CC

L-Editor: A

P-Editor: Ma YJ



CONCLUSION

Adjunctive melatonin therapy has some positive outcomes for sleep, metabolic profile and tardive dyskinesia in patients with schizophrenia. No beneficial effect of melatonin was observed on outcomes of cognition or benzodiazepine discontinuation. Future studies utilizing larger samples and investigations specifically comparing the effect of melatonin as adjunctive therapy with different antipsychotics in patients with schizophrenia are required.

Key Words: Schizophrenia; Melatonin; Clinical trials; Sleep; Metabolic syndrome; Tardive dyskinesia

©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.

Core Tip: This systematic review synthesized the results of clinical trials that have investigated the effect of exogenous melatonin as adjunctive therapy for patients with schizophrenia. Some positive outcomes were demonstrated for sleep improvement and attenuating antipsychotic-induced metabolic side effects. Future investigations are required to determine differential effects of melatonin when used in conjunction with a range of antipsychotic medications.

Citation: Duan C, Jenkins ZM, Castle D. Therapeutic use of melatonin in schizophrenia: A systematic review. *World J Psychiatr* 2021; 11(8): 463-476

URL: <https://www.wjgnet.com/2220-3206/full/v11/i8/463.htm>

DOI: <https://dx.doi.org/10.5498/wjp.v11.i8.463>

INTRODUCTION

Schizophrenia is a chronic psychiatric disorder characterized by a combination of positive (hallucinations and delusions) and negative symptoms affecting thought, perception, cognition and behaviour through complex mechanisms, often resulting in significant deterioration of function[1]. Along with the cardinal features of psychosis, associated side effects of medications and sleep dysfunction can cause lifelong impact on patients' quality of life[2].

Second-generation antipsychotics (SGAs) are the current standard for treating schizophrenia and related illnesses due to the comparatively lower rates of extrapyramidal side effects (EPS), as compared with first generation antipsychotics[3]. However, it has been demonstrated that EPS remain a potential side effect of SGAs[4]; tardive dyskinesia (TD) remains a risk even with these newer agents[5], with limited understanding of both the mechanisms and treatment options[6]. Furthermore, significant weight gain and an increased incidence of metabolic syndrome (MetS) and cardiovascular disease risk have also been established in association with certain SGA medications[7].

Sleep dysfunction is also common in people with schizophrenia, as demonstrated by poor sleep efficiency and disrupted circadian rhythms[8,9]. Studies have shown that there is decreased endogenous secretion of melatonin in patients with schizophrenia, and this pattern can persist despite improvement of sleep quantity and quality with antipsychotic agents[10]. Benzodiazepines (BZDs) are widely used to ameliorate sleep disruption in schizophrenia. While only recommended for short-term use, many patients remain on BZDs long-term, suffering additional effects including sedation, increased risk of falls, and cognitive impairment[11,12].

In an effort to address sleep dysfunction in individuals with schizophrenia, various studies have explored the use of exogenous melatonin. Melatonin (N-acetyl-5-methoxytryptamine) is an endogenously produced hormone naturally secreted at night from the pineal gland in a circadian rhythm to promote sleep. Adjunctive administration of exogenous melatonin has been recognized to have therapeutic benefit in sleep disorders in the general population[13,14]; however, it remains relatively less explored in people with schizophrenia. Furthermore, melatonin has also demonstrated direct and indirect antioxidant and neuroprotective effects, suggesting various potential clinical uses for treatment in schizophrenia, notably EPS and MetS

[15].

The current review aims to synthesize the evidence from clinical trials investigating the effect of adjunctive use of melatonin on any outcome in individuals with schizophrenia.

MATERIALS AND METHODS

The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines were adhered to throughout the review.

Search strategy

The literature search was conducted online for papers in the English language with no restriction of publication date, using MEDLINE (Ovid), Embase, PsychINFO, and PubMed on 27/08/20; and CINAHL and the Cochrane Library on 28/08/20. Syntax was translated using Polyglot to search the databases appropriately. Search terms included the keywords of “schizophrenia”, “melatonin” and with the following trade names – circadin, regulin, benedorm, melaxen or melovine, and “clinical trials” (of any type). Boolean operators OR was used to combine synonyms of the keywords, and AND was used to combine search terms. MeSH headings were specifically used for “schizophrenia”, “melatonin” and “clinical trials” as well as searching for these terms in the title and abstract. Additional studies were identified from a manual search of the reference lists of included articles and registered clinical trials.

Inclusion criteria

The inclusion criteria for papers in this systematic review were: (1) A peer-reviewed research article published in English; (2) Included a group of participants with a diagnosis of schizophrenia (including its subtypes), paraphrenia, delusional psychoses, paranoid psychosis, psychosis not otherwise specified, schizophreniform disorder, schizotypal disorder or schizoaffective disorder; (3) A clinical trial using melatonin as adjunctive therapy; (4) Collected an outcome measure of any duration; and (5) Included original data in the paper. Exclusion criteria included review papers, meta-analyses, case reports, animal studies or studies with patient populations that included neurodegenerative diseases, organic causes of disease, and primary sleep disorders.

Study selection

Search results were exported to Endnote bibliographic management software, duplicates removed, and the remainder uploaded to Covidence systematic review software (www.covidence.org) by Duan C Two authors (Duan C, Castle D) independently screened records on title and abstract and then full text against the exclusion criteria and disagreements were resolved by discussion.

Data extraction and assessment of risk of bias

Two reviewers (Jenkins ZM and Duan C) independently extracted data and consensus was confirmed by a third reviewer (Castle D). Extracted data included information on study characteristics, objectives and outcomes. A meta-analysis was not performed as there were too few similarities across studies in terms of study methods and outcome measures. The risk of bias among included studies was assessed independently by two authors (Duan C and Jenkins ZM) using the Cochrane risk-of-bias tool for randomised trials[16] and consensus was confirmed by a third reviewer (Castle D). Studies were classified into three classes of quality, viz.: low, moderate or high risk of bias. The risk of bias was not used as an exclusion criterion in the selection of studies, to provide a complete overview of available data.

RESULTS

A total of 163 papers were identified from the search and an additional two papers were found from the reference list of the identified papers. Sixty eight duplicate records were excluded and the titles and abstracts of the remaining 97 papers were screened independently by two authors (Duan C and Castle D). After title and abstract screening, 25 papers were read in full and assessed for eligibility. A further 10 papers were excluded, leaving 15 papers included for qualitative synthesis (see [Figure 1](#) for an

Figure Legends




Figure 1 PRISMA flowchart.

overview of the study selection process).

Study characteristics

Characteristics of the 15 included studies for qualitative synthesis are shown in Tables 1-5. Four trials had a crossover design, two were open-label and nine utilized a randomized double-blind parallel design. The 15 trials included a total of 626 participants (351 male, 252 female, 23 not specified) with sample sizes ranging from 10-120. Diagnoses in the studies included 269 participants with schizophrenia, 268 with paranoid schizophrenia, 7 with disorganized schizophrenia, 27 with schizoaffective disorder and 55 with bipolar disorder (the bipolar disorder patients were part of a cohort including people with schizophrenia, hence their inclusion).

Risk of bias

One study was classified as at low risk of bias, nine were classified as having a moderate risk of bias and six were classified as being at high risk of bias (see outcome Tables for overall classification).

Outcome measures

Studies were grouped according to the following primary outcome measures: sleep ($n = 6$; see Table 1), metabolic profile ($n = 3$; see Table 2), TD ($n = 3$; see Table 3), cognitive function ($n = 2$; see Table 4) and BZD tapering ($n = 1$; see Table 5).

Sleep outcomes

Six studies primarily assessed the impact of melatonin therapy on sleep parameters in individuals with schizophrenia[17-22], see Table 1.

Two studies assessed the effect of controlled release melatonin formulation on sleep parameters over a three week period[17,18]; one demonstrated a significant improvement in sleep efficiency over three weeks of melatonin treatment, as compared to placebo[17] while the other reported worsened sleep efficiency, prolonged REM sleep latency and increased duration of wakefulness on the first night, as compared to the second night in participants who received melatonin[18]. Another investigation employed a patient-determined dosage of melatonin over a 15 d period; those who received melatonin had a decreased number of awakenings, increased sleep duration and superior self-report sleep parameters than controls[19].

The impact of melatonin on circadian rhythms was assessed by Mishra *et al*[20] according to change in serum and urinary melatonin levels, which increased over the trial period in participants who received melatonin therapy, compared with controls.

Table 1 Sleep outcomes

Ref.	Sample size (sex) melatonin; control	Age (yr) melatonin; control	Dose, duration	Diagnosis	Inclusion criteria	Study design	Outcomes	Significant findings related to melatonin	Risk of bias
Shamir <i>et al</i> [18], 2000	14 (11 M, 3 F), 14 (11 M, 3 F)	Overall: 42.3 ± 13.1	2 mg CR melatonin or placebo/day for 3 wk	SZA (<i>n</i> = 2); Paranoid SCZ (<i>n</i> = 10); Disorganised SCZ (<i>n</i> = 2)	Diagnosis of chronic SCZ (as per DSM-IV criteria); poor sleep quality	Randomized, double-blind, crossover trial (1 wk washout)	Sleep latency (min), REM sleep (%), REM sleep latency (min), total sleep time (min), sleep efficiency (%), duration of wakefulness (min), stage 1 sleep (%), slow wave sleep (%)	REM Sleep latency (min): Melatonin: 1 st night > 2 nd night Sleep efficiency (%): Melatonin: 1 st night < 2 nd night Duration of wakefulness (min): Melatonin: 1 st night > 2 nd night Stage 1 sleep (%): Placebo: 1 st night < 2 nd night	High
Shamir <i>et al</i> [17], 2000	19 (12 M, 7 F); 19 (12 M, 7 F)	Overall: 42 ± 5	2 mg CR melatonin or placebo/day for 3 wk	SZA (<i>n</i> = 5); Paranoid SCZ (<i>n</i> = 9); Disorganised SCZ (<i>n</i> = 5)	Diagnosis of chronic SCZ (as per DSM-IV criteria); poor sleep quality	Randomized, double-blind, crossover trial (1 wk washout)	Urinary 6-SMT excretion, sleep efficiency (%), sleep latency (min), total sleep time (min), wake after sleep onset duration (min), fragmentation index (%), number of awakenings (N)	Sleep efficiency (%): Melatonin > Placebo	Some concerns
Suresh Kumar <i>et al</i> [19], 2007	20 (13 M, 7 F); 20 (14 M, 6 F)	38.4 ± 14.4; 36.0 ± 13.4	Patient determined dosage of melatonin or placebo for 15 d	Paranoid SCZ (<i>n</i> = 40)	Diagnosis of paranoid SCZ (as per DSM-IV criteria); illness duration < 1 yr; clinically stable; receiving same dose of haloperidol for the past month, insomnia present for past 2 wk	Double-blind, placebo-controlled study	Time taken to fall asleep (min), number of awakenings (n), duration of sleep (min), self-report sleep questionnaire	Number of awakenings (N): Melatonin < Placebo Duration of sleep (min): Melatonin > Placebo Self-report sleep questionnaire: Time to fall asleep, quality of sleep, depth of sleep, freshness on awakening, morning headache, morning mental dullness, mood, overall functioning were superior in Melatonin group <i>vs</i> Placebo	High
Mishra <i>et al</i> [20], 2020	PPS: 30 (15 M, 15 F); 30 (21 M, 9 F). PNS: 30 (21 M, 9 F); 30 (14 M, 16 F)	PPS: 38.6 ± 10.68; 34.0 ± 8.38. PNS: 34.97 ± 12.35; 37.87 ± 3.84	8 mg/d Ramelteon + monotherapy <i>vs</i> monotherapy alone for 4 wk	SCZ (<i>n</i> = 120). Patients were categorized into PPS (<i>n</i> = 60) and PNS (<i>n</i> = 60) groups based on PANSS scoring	Diagnosis of SCZ (as per DSM-5 criteria); aged between 18-65 yr; treatment naive or had not taken treatment for 4 wk	Randomized, open-label, rater-blinded, parallel design clinical trial	Quality of sleep (PSQI), melatonin excretion (urinary melatonin 6aMTs), serum AANAT, symptom severity (PANSS)	Change in serum melatonin at 14:00 h: PPS and PNS: Melatonin > Control Change in serum melatonin 2 h after add on therapy: PPS and PNS: Melatonin > Control Change in urinary melatonin: PPS and PNS: Melatonin > Control Change in serum AANAT: PPS and PNS: Melatonin > Control	High

									PSQI: PPS and PNS: Melatonin > Control	
									Change in PANSS total score: PPS and PNS: Total score improved Melatonin > Control; PPS: Decreased positive symptoms in Melatonin > Control; PNS: Decrease negative symptoms in Melatonin > Control	
Baandrup <i>et al</i> [22], 2016	20 (11 M, 9 F); (18 M, 10 F)	28 47.7 ± 8.2; 45.9 ± 10.3	2 mg/ d PR melatonin or placebo for 24 wk	Paranoid SCZ (n = 38), Non-paranoid SCZ (n = 2), SZA (n = 2), BP (n = 6)	Diagnosis of SCZ, SZA or BP (as per ICD-10 criteria); treated with 1 antipsychotic and 1 BZD for 3 m	Randomized, double-blind clinical trial	Actigraphy (sleep and 24 h rhythm activity variables)	-		Some concerns
Baandrup <i>et al</i> [21], 2016	28 (14 M, 14 F); (15 M, 12 F)	27 48.8 ± 7.1; 49.1 ± 12.2	2 mg/ d PR melatonin or placebo for 24 wk	Paranoid SCZ (n = 42), non-paranoid SCZ (n = 2), SZA (n = 3), BP (n = 8)	Diagnosis of SCZ, SZA or BP (as per ICD-10 criteria); treated with 1 antipsychotic and 1 BZD for 3 mo	Randomized, double-blind clinical trial	PSQI, polysomnography (n = 23; total sleep time, sleep latency, REM latency, time awake after sleep onset, number of awakenings, sleep architecture)		PSQI sleep quality: Melatonin > Placebo	Some concerns

AANAT: Aryl-alkylamine-N-acetyl-transferase; BP: Bipolar disorder; BZD: Benzodiazepine; CR: Controlled-release; DSM-IV: Diagnostic and Statistical Manual of Mental Disorders, fourth edition; F: Female; ICD-10: International Classification of Diseases, Tenth Revision; M: Male; PANSS: Positive and Negative Syndrome Scale; PNS: Predominant negative symptom group; PPS: Predominant positive symptom group; PR: Prolonged-release; PSQI: Pittsburgh sleep quality index; REM: Rapid eye movement; SCZ: Schizophrenia; SZA: Schizoaffective disorder.

Moreover, significant improvements in sleep (as measured by the PSQI) and symptoms of schizophrenia (as measured by the PANSS) were demonstrated by patients who received ramelteon as an add-on to antipsychotic therapy, compared to antipsychotic therapy alone[20].

Two publications reported different sleep outcomes from the same study whose primary aim was to observe the effect of melatonin on BZD discontinuation/reduction in patients with a diagnosis of schizophrenia or bipolar disorder. One reported no difference between add-on melatonin therapy on circadian rest-activity rhythms[22], compared to placebo. However, the other publication highlighted that participants who received melatonin reported superior subjective sleep quality than the placebo group[21].

Metabolic profile outcomes

Three studies assessed whether melatonin attenuates antipsychotic-induced metabolic side effects[23-25], see Table 2.

Modabbernia *et al*[24] investigated the impact of melatonin on patients with first episode schizophrenia. They reported significantly less increase in weight gain, body mass index (BMI) and total cholesterol over an eight week trial as well as significantly greater reductions in psychiatric symptoms (as assessed by the PANSS) in patients who received melatonin when initiating olanzapine, compared to placebo. Another

Table 2 Metabolic outcomes

Ref.	Sample size (sex) melatonin; control	Age (yr) melatonin; control	Dose, duration	Diagnosis	Inclusion criteria	Study design	Outcomes	Significant findings related to melatonin	Risk of bias
Borba <i>et al</i> [23], 2011	14 (8 M, 6 F); 6 (5 M, 1 F)	49 ± 7; 56 ± 9	8 mg/d Ramelton or placebo for 8 wk	SCZ (<i>n</i> = 11), SZA (<i>n</i> = 9)	Diagnosis of SCZ (as per DSM-IV criteria); aged between 18-65 yr; BMI > 27 kg/m ² , insulin resistance or any component of metabolic syndrome or a BMI of > 30 kg/m ²	Double-blind, placebo-controlled pilot trial	Waist circumference (cm), abdominal fat as measured by DEXA, glucose metabolism, C-reactive protein, lipids, psychopathology (PANSS; HDRS, HCQoL), sleep quality (SSS, FSI, MOSSS), adverse effects (SATEE)	Total cholesterol; cholesterol-to-HDL ratio; LDL particle number: Melatonin < Placebo Adverse effects: Melatonin <i>vs</i> control group: drowsiness (57% <i>vs</i> 33%), heart burn (21% <i>vs</i> 0%), cough (21% <i>vs</i> 0%), akathisia (21% <i>vs</i> 0%), increased urinary frequency (14% <i>vs</i> 0%), problems with memory or concentration (21% <i>vs</i> 0%) Arthralgia/myalgia and anxiety: Placebo > Melatonin	High
Modabbernia <i>et al</i> [24], 2014	18 (13 M, 5 F); 18 (12 M, 6 F)	32.7 ± 7.3; 32.8 ± 8.2	3 mg/d melatonin + Olanzapine or placebo + Olanzapine for 8 wk	SCZ (<i>n</i> = 36)	Diagnosis of SCZ (as per DSM-IV criteria); aged between 18-65 yr; in their first-episode eligible for starting olanzapine	Randomized, double-blind, placebo-controlled, and parallel-group study	Anthropometric measures, BP, FBS, fasting plasma insulin, Psychopathology (PANSS)	Weight, BMI and Waist circumference: Melatonin < Placebo PANSS total score: Melatonin < Placebo	Some concerns
Romo-Nava <i>et al</i> [25], 2014	20 (10 M, 10 F); 24 (12 M, 12 F)	Overall: 29.5 ± 8.3	5 mg/d CR melatonin or placebo for 8 wk	SCZ (<i>n</i> = 24); BP (<i>n</i> = 20)	Diagnosis of SCZ or BP type I (as per DSM-IV criteria); aged between 18-45 yr, initiated treatment with SGAs < 3 mo	Double-blind, placebo-controlled study	Anthropometric measures, body composition, BP, Lipids, Glucose, PANSS, CGI-S. BPD only: HDRS, YMRS. Schizophrenia only: CDS	Weight gain, waist circumference, DBP, fat mass, triglycerides: Melatonin (BP only) < Placebo	Some concerns

BMI: Body mass index; BP: Bipolar disorder; BP: Blood pressure; CDS: Calgary depression scale; CGI-S: Clinical Global Impression-Severity of Illness; CR: Controlled-release; DEXA: Dual-energy x-ray absorptiometry; DSM-IV: Diagnostic and Statistical Manual of Mental Disorders, fourth edition; F: Female; FBS: Fasting blood sugar; FSI: Fatigue scale inventory; HCQoL: Heinrichs-Carpenter Quality of Life Scale; HDL: High-density lipoprotein; HDRS: Hamilton Depression Rating Scale; LDL: Low-density lipoprotein; M: Male; MOSSS: Medical outcomes study sleep scale; PANSS: Positive and Negative Syndrome Scale; SATEE: Systematic assessment for treatment emergent events; SCZ: Schizophrenia; SGA: Second generation antipsychotics; SSS: Stanford sleepiness scale; SZA: Schizoaffective disorder; YMRS: Young mania rating scale.

investigation assessed the impact of melatonin on patients with schizophrenia or bipolar disorder taking SGAs[25]. For the group as a whole, melatonin attenuated weight gain, waist circumference increase and was associated with decreased diastolic blood pressure. However, subgroup analysis of participants with schizophrenia alone demonstrated no significant changes as a result of melatonin therapy[25].

Borba *et al*[23] investigated whether melatonin could attenuate the metabolic side-effects of antipsychotics in patients with a pre-existing BMI of above 27 kg/m² and at least one component of MetS. They demonstrated no change in anthropometric outcomes but did observe decreased total cholesterol, cholesterol-to-high-density lipoprotein ratio and low-density lipoprotein (LDL) particle number in those who received melatonin, compared to placebo[23]. Moreover, they reported significantly

Table 3 Tardive dyskinesia

Ref.	Sample size (sex) melatonin; control	Age (yr) melatonin; control	Dose, duration	Diagnosis	Inclusion criteria	Study design	Outcomes	Significant findings related to melatonin	Risk of bias
Shamir <i>et al</i> [26], 2000	19 (8 M, 11 F); 19 (8 M, 11 F)	Overall: 74.0 ± 9.5	2 mg/d CR melatonin or placebo for 4 wk	SCZ (<i>n</i> = 19)	Diagnosis of SCZ of > 20 yr (as per DSM-IV criteria), TD > 5 yr, antipsychotic treatment > 10 yr	Double-blind, placebo-controlled, crossover trial (2 wk washout)	AIMS	-	Some concerns
Shamir <i>et al</i> [27], 2001	22 (11 F, 11 M); 22 (11 F, 11 M)	Overall: 64.2 ± 14.3	10 mg/d CR melatonin or placebo for 6 wk	SCZ (<i>n</i> = 22)	Diagnosis of SCZ and anti-psychotic-induced TD (as per DSM-IV criteria)	Double-blind, placebo-controlled, crossover trial (4 wk washout)	AIMS	AIMS: Melatonin < Placebo	Some concerns
Castro <i>et al</i> [28], 2011	7; 6 (sex NR)	Overall: 59.9 ± 2.7	20 mg/d melatonin or placebo for 12 wk	SCZ (<i>n</i> = 11); BP (<i>n</i> = 2)	Diagnosis of neuroleptic-induced TD (as per DSM-IV criteria)	Randomized, double blind, placebo-controlled pilot study	AIMS; BPRS	-	High

AIMS: Abnormal Involuntary Movement Scale; BP: Bipolar disorder; BPRS: Brief psychiatric rating scale; CR: Controlled-release; DSM-IV: Diagnostic and Statistical Manual of Mental Disorders, fourth edition; F: Female; M: Male; NR: Not reported; SCZ: Schizophrenia; TD: Tardive dyskinesia.

Table 4 Cognitive function

Ref.	Sample size (sex) melatonin; control	Age (yr) melatonin; control	Dose, duration	Diagnosis	Inclusion criteria	Study design	Outcomes	Significant findings related to melatonin	Risk of bias
Shirayama <i>et al</i> [29], 2014	10 (NR); -	42.5 ± 7.3	8 mg/d melatonin for 6 mo	SCZ (<i>n</i> = 10)	Diagnosis of SCZ (as per DSM-IV criteria); symptoms stable for 3 mo	Open-label study	TMT (A and B), WCST, VFT, Stroop Test, DSPDT, IGT, RAVLT	RAVLT (total, delayed recall and recognition): Improved at 6-mo compared to baseline	High
Baandrup <i>et al</i> [30], 2017	40 (21 M, 19 F); 40 (24 M, 16 F)	47.4 ± 8.6; 49.0 ± 12.1	2 mg/d CR melatonin or placebo for 24 wk	Paranoid SCZ (<i>n</i> = 62), non-paranoid SCZ (<i>n</i> = 6), SZA (<i>n</i> = 3), BP (<i>n</i> = 9)	Diagnosis of SCZ, SZA or BP (as per ICD-10 criteria); treated with 1 antipsychotic and 1 BZD for 3 mo	Randomized, double-blind clinical trial	BACS (domains: verbal memory, working memory, motor speed, verbal fluency, letter fluency, attention and processing speed, executive function), WHO-Five WBI, SWN, PSP, UKU, PANSS	-	Low

BACS: Brief assessment of cognition in schizophrenia; BP: Bipolar disorder; BZD: Benzodiazepine; CR: Controlled-release; DSM-IV: Diagnostic and Statistical Manual of Mental Disorders, fourth edition; DSPDT: Digit span distraction test; F: Female; ICD-10: International Classification of Diseases, Tenth Revision; IGT: Iowa gambling task; M: Male; NR: Not reported; PANSS: Positive and negative syndrome scale; PSP: Personal and social performance scale; RAVLT: Rey auditory verbal learning test; SCZ: Schizophrenia; SWN: Subjective wellbeing under neuroleptic treatment scale; SZA: Schizoaffective disorder; TMT: Trail-making test; part A and part B; UKU: Udvalget for Kliniske Undersoegelser side effect rating scale; VFT: Verbal fluency test; WCST: Wisconsin card sorting test; WHO-Five WBI: WHO-five wellbeing index.

lower levels of arthralgia/myalgia and anxiety, yet significantly more side effects of drowsiness (57% *vs* 33%), heart burn (21% *vs* 0%), cough (21% *vs* 0%), akathisia (21% *vs* 0%), increased urinary frequency (14% *vs* 0%), and problems with memory or concentration (21% *vs* 0%) in those who received melatonin in comparison with those on placebo[23].

Table 5 Benzodiazepine discontinuation

Ref.	Sample size (sex) melatonin; control	Age (yr) melatonin; control	Dose, duration	Diagnosis	Inclusion criteria	Study design	Outcomes	Significant findings	Risk of bias
Baandrup <i>et al</i> [12], 2016	42 (23 M, 19 F); 44 (25 M, 19 F)	47.9 ± 8.7; 49.4 ± 12.3	2 mg/d PR melatonin or placebo for 24 wk	Paranoid SCZ (<i>n</i> = 67), Non-paranoid SCZ (<i>n</i> = 6), SZA (<i>n</i> = 3), BP (<i>n</i> = 10)	Diagnosis of SCZ, SZA or BP (as per ICD-10 criteria); treated with 1 antipsychotic drug and 1 BZD drug for 3 mo; able to understand Danish	Randomized, double-blind clinical trial	Mean daily dosage of BZD, pattern of BZD dosage, BZD cessation proportion, BWSQ-2	-	Some concerns

BP: Bipolar disorder; BWSQ-2: Benzodiazepine Withdrawal Symptom Questionnaire; BZD: Benzodiazepine; ICD-10: International Classification of Diseases, Tenth Revision; PR: Prolonged release; SCZ: Schizophrenia; SZA: Schizoaffective disorder.

TD

Three studies investigated the impact of melatonin therapy on symptoms of TD[26-28], see Table 3.

The use of 2 mg/d adjunctive melatonin therapy over a four week period did not affect severity of TD in an initial study by Shamir *et al* [26]. However, a follow-on study from the same investigators found that 10 mg/d of melatonin over a six week period was associated with a significant decrease in TD severity (as measured by the Abnormal Involuntary Movement Scale; AIMS) in patients with chronic schizophrenia, as compared to placebo[27]. In a more recent study, however, Castro *et al*[28] used 20 mg/d of melatonin over a 12 wk period, yet did not observe any difference from placebo in terms of TD symptoms.

Cognitive function

Two studies investigated the impact of melatonin on cognitive function in people with schizophrenia, over a period of 24 wk[29,30], see Table 4.

The only significant change in cognitive function associated with melatonin treatment was improved memory on a verbal learning task post-treatment (8 mg/d for six months), as compared to baseline levels in one of these studies[29]. In contrast, Baandrup *et al*[30] did not report any change in any domain of cognitive functioning – as assessed by the Brief Assessment of Cognition in Schizophrenia (BACS) cognitive battery – in patients receiving 2 mg/d prolonged-release melatonin for 24 wk.

Benzodiazepine discontinuation

Baandrup *et al*[21,22,30] investigated the impact of melatonin during discontinuation or reduction of BZDs and reported various outcomes in four papers, three of which are reported above. Overall, they found that add-on melatonin did not impact average BZD dosage, dosage pattern, cessation proportions or BZD withdrawal symptoms over their 24-wk trial, see Table 5[12].

DISCUSSION

The current review provides a synthesis of investigations using melatonin for individuals with schizophrenia, across a diverse range of outcomes. The various outcomes identified are discussed below.

Sleep

The impact of melatonin on sleep function was the most commonly reported outcome in the current review, with some positive outcomes. Two studies assessed the efficacy of melatonin in improving sleep efficiency (defined as proportion of time asleep over total time in bed). One demonstrated improved efficiency[17] while one reported worsened sleep efficiency[18]. However, the worsened sleep efficiency (and accompanying prolonged REM sleep latency and increased duration of wakefulness) was a comparison between sleep parameters on the first night to the second night of the study. The study objective was to investigate the impact of melatonin on 'the first

night effect (FNE)', whereby individuals have a tendency to experience poorer sleep quality on the first night of a sleep evaluation study[18]. Therefore, while this study demonstrated that melatonin does not ameliorate the FNE, conclusions cannot be drawn about extended sleep efficiency.

The only study in the current review that permitted a patient-determined dosage of melatonin revealed a significantly lower number of night-time awakenings, a longer duration of sleep and improved subjective sleep quality in patients with schizophrenia and comorbid insomnia, as compared to placebo[19]. While the modal dose of melatonin over the trial was 3 mg/d, the authors conceded that conclusions could not be made regarding the optimal dose of melatonin for improved sleep outcomes. Moreover, they did not employ an objective measure of sleep, such as polysomnographic or actigraphic assessments, recommending that further investigation is required[19].

The impact of melatonin on circadian rhythm was assessed in two studies; increased objective measures of serum and urinary melatonin were observed in patients who received melatonin[20], yet actigraphic observations of circadian rhythm revealed no change with melatonin treatment[22]. However, the actigraphic assessments were taken in patients who were concurrently discontinuing BZD medication, limiting generalisation. The same investigation reported improved subjective sleep quality in patients tapering off BZDs[21], suggestive of some beneficial impacts of melatonin.

Overall, melatonin's main indication has been to treat disorders of sleep based on its physiological regulatory effects. In mental health populations, there has been increasing use in treatment of disorders that have a sleep dysfunction component[31]. In patients with schizophrenia, exogenous melatonin induced secretion of endogenous melatonin in a single study and improved sleep efficiency in another. Future replications utilizing a controlled melatonin dosage, free from the impact of BZD discontinuation, are required in order to clarify the indications for melatonin on sleep in people with schizophrenia.

Metabolic profile outcomes

The efficacy of melatonin in ameliorating metabolic side effects of antipsychotics among patients with schizophrenia was explored in three studies; two of which reported some benefits[23,24].

Adjunctive treatment of melatonin was effective in attenuating weight gain in first episode schizophrenia patients who were initiating treatment with olanzapine[24]. However, no significant benefit of melatonin on body weight were observed in two separate studies of patients with an established history of antipsychotic treatment[23, 25]. A tentative interpretation of these findings is that the use of melatonin in conjunction with the initiation of antipsychotic treatment may assist in the initial weight gain associated with first episode psychosis and initiation of antipsychotics[32, 33], but further studies are required.

The only other beneficial metabolic outcome was an improvement in total cholesterol and LDL-particle number in participants who received ramelteon in a pilot study[23]. However, the inclusion criteria for that study specified patients with a pre-existing BMI of above 27 and a component of the MetS, therefore it may be that melatonin is more effective for those with poorer initial metabolic health. There is also the possibility of the finding simply reflecting regression to the mean. While no significant beneficial impact on lipid profile was seen in the larger studies included in this review, there was a trend towards improvement in triglyceride levels in first episode patients[24]; further studies are required.

Given that some metabolic outcomes were improved in patients with schizophrenia [23,24] and bipolar disorder[25] taking antipsychotic medication, and a recent animal study demonstrated efficacy of melatonin in attenuating antipsychotic-induced weight gain[34], there are positive indications for the adjunctive use of melatonin. It was also suggested that the variation in efficacy may be partly explained by the relative metabolic risk associated with different antipsychotics[25]. Melatonin reduced weight gain in patients receiving medium risk antipsychotics (quetiapine and risperidone), an effect that was not seen in patients receiving high risk antipsychotics (clozapine and olanzapine)[25]. Therefore, future studies should also investigate the differential impact of adjunctive melatonin therapy on individual antipsychotic medications.

TD

Three studies in the current review assessed the impact of melatonin on TD severity using the AIMS, with one group suggesting that both duration and dosage of melatonin therapy are pertinent to alleviating symptoms of TD. Shamir *et al*[27] initially found no beneficial impact of a low dose of melatonin on TD, yet their later

investigation using a higher dose of melatonin for a prolonged period suggested clinical efficacy for symptoms of TD[27]. However, these results were not replicated in a further study[28]. While melatonin has demonstrated efficacy in attenuating symptoms of TD in animal models, it has been suggested that this may be due to anti-dopaminergic activity masking the movements, as opposed to treating TD *per se*[35].

Cognitive function

It is well established that schizophrenia is associated with impairments across a wide range of cognitive domains[36]. The current review identified only one study whose primary objective was to observe the effect of add-on melatonin on cognitive function in patients with schizophrenia[29]. While a test of memory function (RAVLT) improved over six months in patients with schizophrenia, this improvement was in comparison to baseline assessments rather than controls[29]. Moreover, given the study design was open-label and conducted in a small sample size, this result requires further replication. Cognitive outcomes were assessed as a secondary outcome in a separate study whose primary objective was to observe the efficacy of melatonin as facilitator of reduction or discontinuation of chronic use of BZDs[30]. No cognitive improvements were observed in the cognitive battery (BACS), consistent with the literature suggesting that pharmacological adjuncts are yet to prove effectiveness in significantly enhancing cognition in patients with schizophrenia[37].

BZD discontinuation

One study in the current review investigated the effects of melatonin in facilitating reduction or discontinuation of chronic use of BZDs in patients with schizophrenia [12], concluding that adjunctive melatonin had no significant effect on BZD dosage or cessation over 24 wk. Moreover, any interpretation of secondary outcomes from this investigation would need to be considered within the context of BZD withdrawal.

Limitations

The interpretations from the current review are limited by the small sample sizes of included studies. Melatonin formulations and dosages differed across studies. Moreover, risk of bias assessment indicated that only one study was deemed at low risk of bias, with the remainder carrying moderate or high risk of bias. Furthermore, some samples included patients with diagnoses of schizophrenia and bipolar disorder, making it difficult to delineate the effect of melatonin for schizophrenia alone. It remains an open question whether efficacy of melatonin for sleep in people with schizophrenia endures over the longer term: future studies should address this important topic.

CONCLUSION

The current review synthesized the results of clinical trials investigating the effect of adjunctive melatonin therapy on any outcome in patients with schizophrenia. To date, investigated outcomes include sleep function, metabolic benefits, TD attenuation, cognitive function and as an adjunct to BZD discontinuation. Positive outcomes were demonstrated for the use of melatonin in improving sleep efficiency and circadian rhythm as well as certain metabolic outcomes, specifically in first-episode patients initiating antipsychotic treatment. One study reported benefit for the use of melatonin in attenuating TD, but this was not found in other studies. There was no observed benefit for the use of melatonin in improving cognitive function or facilitating BZD discontinuation in individuals with schizophrenia. Given that the pharmacokinetics of melatonin and interactions with other drugs are unclear, future studies investigating these in relation to specific antipsychotic medications are required. Moreover, the range of melatonin dosage used and the duration of the studies in the current review highlights that there is currently no standardized melatonin recommendation and the effects of contamination and different formulations are unknown.

ARTICLE HIGHLIGHTS

Research background

Schizophrenia is a chronic psychiatric condition consisting of positive and negative

symptoms causing significant impacts on life. Current treatment includes second-generation antipsychotics (SGAs), the use of which is associated with side effects including: increased metabolic risk, sleep dysfunction and extrapyramidal side effects (EPS). Exogenous melatonin has been demonstrated to attenuate sleep dysfunction in the general population, however its indication in schizophrenia has been relatively unexplored. The proven antioxidant and neuroprotective effects of melatonin suggest potential for therapeutic benefit in adjunctive treatment of schizophrenia, especially in attenuating side effects associated with SGAs.

Research motivation

Current therapeutic treatment for schizophrenia often causes side effects including increased cardiovascular and metabolic risk, sleep dysfunction and EPS. Adjunctive use of melatonin has been suggested to benefit sleep disturbances, however its indication in schizophrenia has remained unclear. Therefore, we synthesized the current evidence for the effect of adjunctive use of melatonin on any outcome in individuals with schizophrenia.

Research objectives

To synthesize clinical trials conducted to date that have investigated the use of melatonin as an adjunctive therapy for individuals with schizophrenia in improving any therapeutic outcome.

Research methods

A systematic literature search was conducted on MEDLINE (Ovid), Embase, PsychINFO, PubMed, CINAHL and Cochrane Library for clinical trials using melatonin as an adjunctive therapy that included a group of patients with schizophrenia. PRISMA guidelines were adhered to and the Cochrane risk-of-bias tool for randomized controlled trials was used by two authors to assess the trials independently, with consensus confirmed by a third reviewer.

Research results

A total of 15 trials were included for qualitative synthesis after assessing for eligibility and removing duplicates. The trials assessed the following primary outcomes: sleep ($n = 6$), metabolic profile ($n = 3$), tardive dyskinesia ($n = 3$), cognitive function ($n = 2$) and benzodiazepine discontinuation ($n = 1$).

Research conclusions

Positive outcomes were demonstrated for the use of melatonin in improving sleep efficiency and certain metabolic outcomes, specifically in first-episode patients initiating antipsychotic treatment. Currently, there is limited therapeutic indication for the use of melatonin in treatment of tardive dyskinesia, cognitive function or facilitating benzodiazepine discontinuation. Limitations included small sample sizes and no standardization of the duration and/or dosage of adjunctive melatonin used.

Research perspectives

Future studies are required to confirm these improvements, determine the pharmacokinetic interactions of melatonin with specific antipsychotic medications and develop a standardized duration and dosage of adjunctive melatonin treatment. Moreover, a long-term safety and efficacy profile remains to be determined.

REFERENCES

- 1 **Freedman R.** Schizophrenia. *N Engl J Med* 2003; **349**: 1738-1749 [PMID: 14585943 DOI: 10.1056/NEJMra035458]
- 2 **Benson KL.** Sleep in schizophrenia: impairments, correlates, and treatment. *Psychiatr Clin North Am* 2006; **29**: 1033-45; abstract ix [PMID: 17118280 DOI: 10.1016/j.psc.2006.08.002]
- 3 **Leucht S, Pitschel-Walz G, Abraham D, Kissling W.** Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. *Schizophr Res* 1999; **35**: 51-68 [PMID: 9988841 DOI: 10.1016/s0920-9964(98)00105-4]
- 4 **Divac N, Prostran M, Jakovceviski I, Cerovac N.** Second-generation antipsychotics and extrapyramidal adverse effects. *Biomed Res Int* 2014; **2014**: 656370 [PMID: 24995318 DOI: 10.1155/2014/656370]
- 5 **Carbon M, Kane JM, Leucht S, Correll CU.** Tardive dyskinesia risk with first- and second-generation

- antipsychotics in comparative randomized controlled trials: a meta-analysis. *World Psychiatry* 2018; **17**: 330-340 [PMID: 30192088 DOI: 10.1002/wps.20579]
- 6 **Lerner PP**, Miodownik C, Lerner V. Tardive dyskinesia (syndrome): Current concept and modern approaches to its management. *Psychiatry Clin Neurosci* 2015; **69**: 321-334 [PMID: 25556809 DOI: 10.1111/pcn.12270]
 - 7 **Pillinger T**, McCutcheon RA, Vano L, Mizuno Y, Arumham A, Hindley G, Beck K, Natesan S, Efthimiou O, Cipriani A, Howes OD. Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis. *Lancet Psychiatry* 2020; **7**: 64-77 [PMID: 31860457 DOI: 10.1016/S2215-0366(19)30416-X]
 - 8 **Rao ML**, Gross G, Strebel B, Halaris A, Huber G, Bräunig P, Marler M. Circadian rhythm of tryptophan, serotonin, melatonin, and pituitary hormones in schizophrenia. *Biol Psychiatry* 1994; **35**: 151-163 [PMID: 7909693 DOI: 10.1016/0006-3223(94)91147-9]
 - 9 **Monti JM**, Monti D. Sleep in schizophrenia patients and the effects of antipsychotic drugs. *Sleep Med Rev* 2004; **8**: 133-148 [PMID: 15033152 DOI: 10.1016/S1087-0792(02)00158-2]
 - 10 **Monteleone P**, Natale M, La Rocca A, Maj M. Decreased nocturnal secretion of melatonin in drug-free schizophrenics: no change after subchronic treatment with antipsychotics. *Neuropsychobiology* 1997; **36**: 159-163 [PMID: 9396013 DOI: 10.1159/000119377]
 - 11 **Petursson H**, Lader MH. Withdrawal from long-term benzodiazepine treatment. *Br Med J (Clin Res Ed)* 1981; **283**: 643-645 [PMID: 6114776 DOI: 10.1136/bmj.283.6292.643]
 - 12 **Baandrup L**, Lindschou J, Winkel P, Gluud C, Glenthøj BY. Prolonged-release melatonin vs placebo for benzodiazepine discontinuation in patients with schizophrenia or bipolar disorder: A randomised, placebo-controlled, blinded trial. *World J Biol Psychiatry* 2016; **17**: 514-524 [PMID: 26086792 DOI: 10.3109/15622975.2015.1048725]
 - 13 **Ferracioli-Oda E**, Qawasmi A, Bloch MH. Meta-analysis: melatonin for the treatment of primary sleep disorders. *PLoS One* 2013; **8**: e63773 [PMID: 23691095 DOI: 10.1371/journal.pone.0063773]
 - 14 **Auld F**, Maschauer EL, Morrison I, Skene DJ, Riha RL. Evidence for the efficacy of melatonin in the treatment of primary adult sleep disorders. *Sleep Med Rev* 2017; **34**: 10-22 [PMID: 28648359 DOI: 10.1016/j.smrv.2016.06.005]
 - 15 **Morera-Fumero AL**, Abreu-Gonzalez P. Role of melatonin in schizophrenia. *Int J Mol Sci* 2013; **14**: 9037-9050 [PMID: 23698762 DOI: 10.3390/ijms14059037]
 - 16 **Higgins JP**, Savović J, Page MJ, Elbers RG, Sterne JA. Assessing risk of bias in a randomized trial. *Cochrane Handbook Syst Rev Intervent* 2019; 205-228
 - 17 **Shamir E**, Laudon M, Barak Y, Anis Y, Rotenberg V, Elizur A, Zisapel N. Melatonin improves sleep quality of patients with chronic schizophrenia. *J Clin Psychiatry* 2000; **61**: 373-377 [PMID: 10847313 DOI: 10.4088/jcp.v61n0509]
 - 18 **Shamir E**, Rotenberg VS, Laudon M, Zisapel N, Elizur A. First-night effect of melatonin treatment in patients with chronic schizophrenia. *J Clin Psychopharmacol* 2000; **20**: 691-694 [PMID: 11106143 DOI: 10.1097/00004714-200012000-00017]
 - 19 **Suresh Kumar PN**, Andrade C, Bhakta SG, Singh NM. Melatonin in schizophrenic outpatients with insomnia: a double-blind, placebo-controlled study. *J Clin Psychiatry* 2007; **68**: 237-241 [PMID: 17335321 DOI: 10.4088/jcp.v68n0208]
 - 20 **Mishra A**, Maiti R, Mishra BR, Jena M, Nath S, Sahu P. Effect of add-on ramelteon therapy on sleep and circadian rhythm disruption in patients with schizophrenia: A randomized controlled trial. *Eur Neuropsychopharmacol* 2020; **31**: 109-118 [PMID: 31831203 DOI: 10.1016/j.euroneuro.2019.11.008]
 - 21 **Baandrup L**, Glenthøj BY, Jennum PJ. Objective and subjective sleep quality: Melatonin vs placebo add-on treatment in patients with schizophrenia or bipolar disorder withdrawing from long-term benzodiazepine use. *Psychiatry Res* 2016; **240**: 163-169 [PMID: 27107670 DOI: 10.1016/j.psychres.2016.04.031]
 - 22 **Baandrup L**, Fasmer OB, Glenthøj BY, Jennum PJ. Circadian rest-activity rhythms during benzodiazepine tapering covered by melatonin vs placebo add-on: data derived from a randomized clinical trial. *BMC Psychiatry* 2016; **16**: 348 [PMID: 27737649 DOI: 10.1186/s12888-016-1062-8]
 - 23 **Borba CP**, Fan X, Copeland PM, Paiva A, Freudenreich O, Henderson DC. Placebo-controlled pilot study of ramelteon for adiposity and lipids in patients with schizophrenia. *J Clin Psychopharmacol* 2011; **31**: 653-658 [PMID: 21869685 DOI: 10.1097/JCP.0b013e31822bb573]
 - 24 **Modabbernia A**, Heidari P, Soleimani R, Sobhani A, Roshan ZA, Taslimi S, Ashrafi M, Modabbernia MJ. Melatonin for prevention of metabolic side-effects of olanzapine in patients with first-episode schizophrenia: randomized double-blind placebo-controlled study. *J Psychiatr Res* 2014; **53**: 133-140 [PMID: 24607293 DOI: 10.1016/j.jpsychires.2014.02.013]
 - 25 **Romo-Nava F**, Alvarez-Icaza González D, Fresán-Orellana A, Saracco Alvarez R, Becerra-Palars C, Moreno J, Ontiveros Uribe MP, Berlanga C, Heinze G, Buijs RM. Melatonin attenuates antipsychotic metabolic effects: an eight-week randomized, double-blind, parallel-group, placebo-controlled clinical trial. *Bipolar Disord* 2014; **16**: 410-421 [PMID: 24636483 DOI: 10.1111/bdi.12196]
 - 26 **Shamir E**, Barak Y, Plopsy I, Zisapel N, Elizur A, Weizman A. Is melatonin treatment effective for tardive dyskinesia? *J Clin Psychiatry* 2000; **61**: 556-558 [PMID: 10982197 DOI: 10.4088/jcp.v61n0803]
 - 27 **Shamir E**, Barak Y, Shalman I, Laudon M, Zisapel N, Tarrasch R, Elizur A, Weizman R. Melatonin treatment for tardive dyskinesia: a double-blind, placebo-controlled, crossover study. *Arch Gen*

- Psychiatry* 2001; **58**: 1049-1052 [PMID: [11695951](#) DOI: [10.1001/archpsyc.58.11.1049](#)]
- 28 **Castro F**, Carrizo E, Prieto de Rincón D, Rincón CA, Asián T, Medina-Leendertz S, Bonilla E. Effectiveness of melatonin in tardive dyskinesia. *Invest Clin* 2011; **52**: 252-260 [PMID: [21950196](#)]
- 29 **Shirayama Y**, Takahashi M, Suzuki M, Tsuruoka Y, Sato K. Effects of Add-on Ramelteon on Cognitive Impairment in Patients with Schizophrenia: An Open-label Pilot Trial. *Clin Psychopharmacol Neurosci* 2014; **12**: 215-217 [PMID: [25598825](#) DOI: [10.9758/cpn.2014.12.3.215](#)]
- 30 **Baandrup L**, Fagerlund B, Glenthøj B. Neurocognitive performance, subjective well-being, and psychosocial functioning after benzodiazepine withdrawal in patients with schizophrenia or bipolar disorder: a randomized clinical trial of add-on melatonin vs placebo. *Eur Arch Psychiatry Clin Neurosci* 2017; **267**: 163-171 [PMID: [27400927](#) DOI: [10.1007/s00406-016-0711-8](#)]
- 31 **Janicak PG**, Kledzik AM, Thorne MC. The role of melatonin in psychiatric disorders. *Psychopharm Rev* 2011; **46**: 49-55 [DOI: [10.1097/01.PSYPHR.0000399579.42651.8b](#)]
- 32 **Addington J**, Mansley C, Addington D. Weight gain in first-episode psychosis. *Can J Psychiatry* 2003; **48**: 272-276 [PMID: [12776395](#) DOI: [10.1177/070674370304800412](#)]
- 33 **Strassnig M**, Miewald J, Keshavan M, Ganguli R. Weight gain in newly diagnosed first-episode psychosis patients and healthy comparisons: one-year analysis. *Schizophr Res* 2007; **93**: 90-98 [PMID: [17478082](#) DOI: [10.1016/j.schres.2007.02.024](#)]
- 34 **Miron IC**, Popescu F, Enăchescu V, Cristea OM, Stoicănescu EC, Amzoiu E, Amzoiu M, Popescu FD. Combination of Olanzapine Pamoate with Melatonin and Metformin: Quantitative Changes in Rat Adipose Tissue. *Curr Health Sci J* 2019; **45**: 372-382 [PMID: [32110439](#) DOI: [10.12865/CHSJ.45.04.05](#)]
- 35 **Nelson LA**, McGuire JM, Hausafus SN. Melatonin for the treatment of tardive dyskinesia. *Ann Pharmacother* 2003; **37**: 1128-1131 [PMID: [12841828](#) DOI: [10.1345/aph.1C460](#)]
- 36 **Schaefer J**, Giangrande E, Weinberger DR, Dickinson D. The global cognitive impairment in schizophrenia: consistent over decades and around the world. *Schizophr Res* 2013; **150**: 42-50 [PMID: [23911259](#) DOI: [10.1016/j.schres.2013.07.009](#)]
- 37 **Harvey PD**, Bowie CR. Cognitive enhancement in schizophrenia: pharmacological and cognitive remediation approaches. *Psychiatr Clin North Am* 2012; **35**: 683-698 [PMID: [22929873](#) DOI: [10.1016/j.psc.2012.06.008](#)]



Published by **Baishideng Publishing Group Inc**
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Telephone: +1-925-3991568

E-mail: bpgoffice@wjgnet.com

Help Desk: <https://www.f6publishing.com/helpdesk>

<https://www.wjgnet.com>

